Evidence map›Paper›PMID 41020525›Full record

ArticleFuture oncology (London, England)2026

Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.

Gang Chen, Yuhan Bao, Yidan Wang, Jianqiao Cao, Chao Yu, Guangdong Qiao, Yizi Cong

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Gang ChenDepartment of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China.
Yuhan BaoBreast Center, The Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
Yidan WangDepartment of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China.
Jianqiao CaoDepartment of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China.
Chao YuDepartment of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China.
Guangdong QiaoDepartment of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China.
Yizi CongDepartment of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs). RESEARCH DESIGN AND

methods581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.

resultsAmong patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.

conclusionsThe SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.

Indexed as

Breast NeoplasmsSentinel Lymph NodeAdultAgedBiomarkers, TumorFemaleFibrinogenHumansLymphatic MetastasisMiddle AgedPrognosisROC CurveSentinel Lymph Node BiopsyThrombin TimeBiomarkers, TumorFibrinogenactivated partial thromboplastin timeBreast cancermetastasissentinel lymph nodethrombin time

Identifiers

PMID41020525
PMCPMC13048600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.